Documents
A list of downloadable documents created during development.
Background information
Multiple myeloma (first line) - bortezomib and thalidomide: equality impact assessment
Multiple myeloma (first line) - bortezomib and thalidomide: final appraisal determination (post appeal)
Multiple myeloma (first line) - bortezomib and thalidomide: appeal
Multiple myeloma (first line) - bortezomib and thalidomide: final appraisal determination
-
Multiple myeloma (first line) - bortezomib and thalidomide: consultee and commentator comments on the ACD
-
Multiple myeloma (first line) - bortezomib and thalidomide: manufacturer comments
-
Multiple myeloma (first line) - bortezomib and thalidomide: Janssen-Cilag
-
Multiple myeloma (first line) - bortezomib and thalidomide: patient and professional groups
-
Multiple myeloma (first line) - bortezomib and thalidomide: commentator comments
Multiple myeloma (first line)- bortezomib and thalidomide: appraisal consultation
-
Multiple myeloma (first line)- bortezomib and thalidomide: appraisal consultation
-
Multiple myeloma (first line)- bortezomib and thalidomide: evaluation report
-
Overview 327.01 KB
-
Assessment report
-
Assessment report 1.95 MB
-
Consultee and commentator comments on the assessment report
-
Celgene 27.26 KB
-
Janssen Cilag 94.67 KB
-
Leukaemia Care 59.2 KB
-
MRC Trial Management Group 24.72 KB
-
Myeloma UK 36.56 KB
-
NHS Quality Improvement Scotland 25.85 KB
-
Royal College of Pathologists 56.55 KB
-
UK Myeloma Forum 26.57 KB
-
MMIX clarification request 57.84 KB
-
Non-manufacturer submissions
-
Myeloma UK (Supported by Leukaemia CARE and Macmillan Cancer Support)
-
Royal College of Pathologists 56.55 KB
-
UK Myeloma Forum 49.97 KB
-
Manufacturer submissions
-
Celgene 51.86 KB
-
Janssen Cilag 110.25 KB